Original news source: https://www.facebook.com/photo.php?fbid=1404385601731090&set=a.747732450729745&id=100064789896714
Japan has approved two pioneering medical treatments using Induced Pluripotent Stem Cells (iPS cells), marking a significant step in regenerative medicine and potentially making them the world’s first commercially available therapies based on this technology.
One of the treatments, called Amchepry, was developed by Sumitomo Pharma to treat patients suffering from Parkinson’s disease. The therapy works by transplanting brain cells derived from iPS cells into patients. These cells are designed to replace damaged neurons responsible for producing dopamine, a chemical that plays a key role in controlling movement. Loss of dopamine-producing cells is one of the main causes of Parkinson’s disease symptoms such as tremors and difficulty with movement.
In another breakthrough, Japanese medical startup Cuorips has developed ReHeart, an innovative treatment aimed at helping patients with severe heart failure. The therapy uses a thin sheet of heart muscle cells created from iPS cells. When placed on the patient’s heart, the sheet helps stimulate the growth of blood vessels and supports improved heart function.
Early clinical trials conducted by researchers at Kyoto University have shown encouraging results. The studies reported strong safety outcomes and noticeable symptom improvement in some patients who received the treatments.
Experts believe these therapies could become available to patients within the coming months following regulatory approval. However, specialists emphasize that ongoing research and careful monitoring will be essential to ensure the long-term safety and effectiveness of these new medical technologies.
Japan has been a global leader in iPS cell research since the discovery of the technology by scientist Shinya Yamanaka, and the approval of these treatments highlights the country’s continued leadership in advancing regenerative medicine. If successful, these therapies could open the door for new treatments for a wide range of diseases in the future.
